Semaglutides effects on gastric emptying and reduced food intake can lead to dehydration if you are not consciously maintaining water intake
Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment)
The implication is that more agonism is better is going to age very poorly as a default assumption, and any clinician or biohacker still defaulting to it in 2030 is going to look like the cardiologists who were still reaching for first-generation beta-blockers in 1995
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Choosing between semaglutide and tirzepatide for weight loss depends on individual patient needs and responses
The exception is the maximum dose for Ozempic (2 mg), which stays at $499 per month